Home › Funds › Amundi US › GILD
Amundi US position in GILD
GILEAD SCIENCES INC · Health Care
Amundi US reported holding 11,259,657 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$1.68B, representing 0.39% of its reported portfolio and ranking #44 among its reported holdings. Amundi US has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Amundi US's GILD position evolved
Amundi US first disclosed a stake in GILD in Q3 2021 at 10,443,516 shares (US$729.5M). The position peaked in Q3 2026 at 11,259,657 shares, worth US$1.68B. Across 21 filings, Amundi US increased the stake 11 time(s), trimmed it 8 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 11,259,657 shares valued at US$1.68B — an increase of 1,487,219 shares quarter over quarter.. Notable position changes include a 38% trim in Q1 2022 (shares rose 3% over the following quarter), a 34% trim in Q4 2024 (shares rose 21% over the following quarter), a 28% trim in Q3 2025 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 10.44M | $729.46M | New |
| Q4 2021 | 10.94M | $788.10M | Add |
| Q1 2022 | 6.82M | $412.18M | Reduce |
| Q2 2022 | 8.08M | $499.65M | Add |
| Q3 2022 | 10.21M | $658.72M | Add |
| Q4 2022 | 10.19M | $885.69M | Hold |
| Q1 2023 | 10.63M | $887.55M | Add |
| Q2 2023 | 10.92M | $838.28M | Add |
| Q3 2023 | 10.60M | $817.83M | Reduce |
| Q4 2023 | 10.52M | $896.39M | Reduce |
| Q1 2024 | 9.50M | $640.29M | Reduce |
| Q2 2024 | 11.24M | $751.44M | Add |
| Q3 2024 | 13.62M | $1.16B | Add |
| Q4 2024 | 9.02M | $805.42M | Reduce |
| Q1 2025 | 8.85M | $994.99M | Reduce |
| Q2 2025 | 10.47M | $1.17B | Add |
| Q3 2025 | 7.58M | $861.37M | Reduce |
| Q4 2025 | 9.52M | $1.17B | Add |
| Q1 2026 | 10.54M | $1.47B | Add |
| Q2 2026 | 9.77M | $1.23B | Reduce |
| Q3 2026 | 11.26M | $1.68B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 58.27M sh · $8.68B · Q3 2026
- Invesco Ltd 38.66M sh · $5.76B · Q3 2026
- Capital World Investors 35.93M sh · $5.36B · Q3 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Capital Research Global Investors 23.98M sh · $3.57B · Q3 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
- MFS Investment Management 11.46M sh · $1.77B · Q3 2026
- Deutsche Bank AG 9.61M sh · $1.43B · Q3 2026
- Boston Partners 6.52M sh · $970.37M · Q3 2026
FAQ
How long has Amundi US held GILD?
Amundi US has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.
What is Amundi US's current position in GILD?
As of Q3 2026, Amundi US holds 11.26M shares of GILD (GILEAD SCIENCES INC), valued at $1.68B, representing 0.39% of its reported portfolio and ranking #44.
Has Amundi US been buying or selling GILD?
In the latest 13F filing (Q3 2026), Amundi US increased its position in GILD. The position peaked in Q3 2026 at 11.26M shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.